secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001193125-25-318469
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna reports positive topline data from Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome
--------------------------------------------------------------------------------

- Positive topline data from registrational Phase 2 trial of miv-cel (KYV-101) in stiff person syndrome (SPS).
- Trial KYSA-8 evaluates fully human autologous CD19 CAR T-cell therapy with CD28 co-stimulation.
- Company to host conference call on Dec 15, 2025 at 8:00 AM ET to discuss results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525318469/0001193125-25-318469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525318469/d33692d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-318469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer